Journals / Turkish journal of vascular surgery / 2019 / Cilt: 28 - Sayı: 2

Methylenetetrahydrofolate reductase polymorphisms in acute deep vein thrombosis

Pages
69–72
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The MTHFR C677T and A1298C gene polymorphisms of thesamples were identified using the real-time polymerase chain reaction.Results: There was no statistically significant difference in the polymorphisms and allele frequencies of the MTHFR C677T andA1298C genes between the patient and control groups (p>0.05).Conclusion: In this study, the MTHFR C677T and A1298C gene polymorphisms were not found to be risk factors for acute DVT.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In this study, we aimed to investigate the effectiveness of methylenetetrahydrofolate reductase (MTHFR) C677T andA1298C gene polymorphisms in acute deep vein thrombosis (DVT).Patients and methods: Between January 2017 and May 2018, a total of 64 patients (37 males, 27 females; mean age 35±18 years;range 19 to 59 years) who were followed with the diagnosis of acute DVT and 64 healthy controls (35 males, 29 females; mean age 43±14 years;range 23 to 57 years) without any vascular pathology were included.
📊
Key Findings & Data:Objectives: In this study, we aimed to investigate the effectiveness of methylenetetrahydrofolate reductase (MTHFR) C677T andA1298C gene polymorphisms in acute deep vein thrombosis (DVT).Patients and methods: Between January 2017 and May 2018, a total of 64 patients (37 males, 27 females; mean age 35±18 years;range 19 to 59 years) who were followed with the diagnosis of acute DVT and 64 healthy controls (35 males, 29 females; mean age 43±14 years;range 23 to 57 years) without any vascular pathology were included.
💡
Conclusion & Impact:The MTHFR C677T and A1298C gene polymorphisms of thesamples were identified using the real-time polymerase chain reaction.Results: There was no statistically significant difference in the polymorphisms and allele frequencies of the MTHFR C677T andA1298C genes between the patient and control groups (p>0.05).Conclusion: In this study, the MTHFR C677T and A1298C gene polymorphisms were not found to be risk factors for acute DVT.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: In this study, we aimed to investigate the effectiveness of methylenetetrahydrofolate reductase (MTHFR) C677T andA1298C gene polymorphisms in acute deep vein thrombosis (DVT).Patients and methods: Between January 2017 and May 2018, a total of 64 patients (37 males, 27 females; mean age 35±18 years;range 19 to 59 years) who were followed with the diagnosis of acute DVT and 64 healthy controls (35 males, 29 females; mean age 43±14 years;range 23 to 57 years) without any vascular pathology were included. The MTHFR C677T and A1298C gene polymorphisms of thesamples were identified using the real-time polymerase chain reaction.Results: There was no statistically significant difference in the polymorphisms and allele frequencies of the MTHFR C677T andA1298C genes between the patient and control groups (p>0.05).Conclusion: In this study, the MTHFR C677T and A1298C gene polymorphisms were not found to be risk factors for acute DVT.

🔖

Cite This Article

ŞENOL, S., KARGÜN, K. (2019). Methylenetetrahydrofolate reductase polymorphisms in acute deep vein thrombosis. Turkish journal of vascular surgery, Cilt: 28 - Sayı: 2, 69–72. https://ajindex.com/articles/375763

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Kızıltepe U, Oktar L, Ergül G, Gelişen İ. Efficiency of the low molecular weight heparin in treatment of deep vein thrombosis. Turk J Vasc Surg 2003;12:15-20
  2. Nicolaides AN, Allegra C, Bergan J, Bradbury A, Cairols M, Carpentier P, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol 2008;27:1-59
  3. Cohen AT, Alikhan R, Arcelus JI, Bergmann JF, Haas S, Merli GJ, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005;94:750-9
  4. Ghaffari K, Ghasemi A, Ghotaslou A, Mohammadi M, Salmanpour Z. Correlation between C677T and A1298C mutations on the MTHFR gene with plasma homocysteine levels and venous thrombosis in pregnant women at risk of thrombosis. Zahedan J Res Med Sci 2015;17:e5192
  5. Brezovska-Kavrakova J, Krstevska M, Bosilkova G, Alabakovska S, Panov S, Orovchanec N. Hyperhomocysteinemia and of Methylenetetrahydrofolate Reductase (C677T) Genetic Polymorphism in Patients with Deep Vein Thrombosis. Mater Sociomed 2013;25:170-4
  6. Gu Y, Liu Z, Li L, Guo CY, Li CJ, Wang LS, et al. OLR1, PON1 and MTHFR gene polymorphisms, conventional risk factors and the severity of coronary atherosclerosis in a Chinese Han population. Cell Physiol Biochem 2013;31:143-52
  7. Spiroski I, Kedev S, Antov S, Arsov T, Krstevska M, Dzhekova-Stojkova S, et al. Methylenetetrahydrofolate reductase (MTHFR-677 and MTHFR-1298) genotypes and haplotypes and plasma homocysteine levels in patients with occlusive artery disease and deep venous thrombosis. Acta Biochim Pol 2008;55:587-94
  8. Norgren L, Hiatt WR, Dormandy JA, NehlerMR, Haris KA, Fowkes FGR. TASC II Working Group. InterSociety consensus for the management of peripheral arterial disease (TASCII). Eur J Vasc Endovasc Surg 2007;33 Suppl 1:S1-75
  9. Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev 2009;23:225-9
  10. Eroğlu E, Arı M. The efficacy and safety of pharmacomechanical thrombolysis and medical therapy for symptomatic deep venous thrombosis. Turk J Vasc Surg 2016;25:128-33
  11. Shaheen K, Alraies MC, Alraiyes AH, Christie R. Factor V Leiden: how great is the risk of venous thromboembolism? Cleve Clin J Med 2012;79:265-72
  12. Hoţoleanu C, Chouki E. Hyperhomocysteinemia and methylenetetrahydrofolate reductase gene polymorphism C677T: risk factors for venous and arterial thrombosis. Rom J Biochem 2013;50:29-37
  13. Milio G, Siragusa S, Minà C, Amat